These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21036884)

  • 21. beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
    Cullen KJ; Schumaker L; Nikitakis N; Goloubeva O; Tan M; Sarlis NJ; Haddad RI; Posner MR
    J Clin Oncol; 2009 Dec; 27(36):6222-8. PubMed ID: 19917838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study.
    Fukada J; Shigematsu N; Takeda A; Ohashi T; Tomita T; Shiotani A; Kunieda E; Kawaguchi O; Fujii M; Kubo A
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):417-24. PubMed ID: 19409727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer.
    Herman LC; Chen L; Garnett A; Feldman LE; Smith B; Weichselbaum RR; Spiotto MT
    Oral Oncol; 2014 Jan; 50(1):52-8. PubMed ID: 24055193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
    Pointreau Y; Garaud P; Chapet S; Sire C; Tuchais C; Tortochaux J; Faivre S; Guerrif S; Alfonsi M; Calais G
    J Natl Cancer Inst; 2009 Apr; 101(7):498-506. PubMed ID: 19318632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer.
    Kovács AF; Mose S; Böttcher HD; Bitter K
    Strahlenther Onkol; 2005 Jan; 181(1):26-34. PubMed ID: 15660190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.
    Fayette J; Fontaine-Delaruelle C; Ambrun A; Daveau C; Poupart M; Ramade A; Zrounba P; Neidhardt EM; Péron J; Diallo A; Céruse P
    Oncotarget; 2016 Jun; 7(24):37297-37304. PubMed ID: 27119503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the efficacy and toxicity of two dose levels of cisplatin/5-fluorouracil as the chemoradiotherapy regimen for the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Su NW; Leu YS; Lee JC; Chen YJ; Chen HW; Liu CJ; Chang YF
    Acta Otolaryngol; 2011 Dec; 131(12):1333-40. PubMed ID: 22017375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community.
    Maguire PD; Meyerson MB; Neal CR; Hamann MS; Bost AL; Anagnost JW; Ungaro PC; Pollock HD; McMurray JE; Wilson EP; Kotwall CA
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):698-704. PubMed ID: 14967423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer.
    Lee KC; Lee SH; Lee Y; Park SH; Park J; Cho EK; Shin DB; Lee JH; Kim DY; Kim ST
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):187-91. PubMed ID: 17996392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
    Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
    J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck.
    Posner MR; Colevas AD; Tishler RB
    Semin Oncol; 2000 Aug; 27(4 Suppl 8):13-24. PubMed ID: 10952434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial.
    Hehr T; Classen J; Belka C; Welz S; Schäfer J; Koitschev A; Bamberg M; Budach W
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1423-31. PubMed ID: 15817346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Katori H; Tsukuda M; Taguchi T
    Cancer Chemother Pharmacol; 2007 May; 59(6):789-94. PubMed ID: 17053926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
    Tishler RB; Norris CM; Colevas AD; Lamb CC; Karp D; Busse PM; Nixon A; Frankenthaler R; Lake-Willcutt B; Costello R; Case M; Posner MR
    Cancer; 2002 Oct; 95(7):1472-81. PubMed ID: 12237916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?
    Specenier PM; Vermorken JB
    Cancer Lett; 2007 Oct; 256(2):166-77. PubMed ID: 17673364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current concepts for the management of head and neck cancer: chemotherapy.
    Specenier PM; Vermorken JB
    Oral Oncol; 2009; 45(4-5):409-15. PubMed ID: 18715812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy].
    Bardet E; Bourhis J; Cals L; Fayette J; Guigay J; Hans S; Saint-Guily JL; Lagarde F; Lallemant B; Milano G; Rolland F; Lefebvre JL
    Bull Cancer; 2009 Oct; 96(10):1013-28. PubMed ID: 19744919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.
    Budach W; Hehr T; Budach V; Belka C; Dietz K
    BMC Cancer; 2006 Jan; 6():28. PubMed ID: 16448551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck.
    Tishler RB; Posner MR; Norris CM; Mahadevan A; Sullivan C; Goguen L; Wirth LJ; Costello R; Case M; Stowell S; Sammartino D; Busse PM; Haddad RI
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1036-44. PubMed ID: 16682134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment.
    Haddad R; Tishler RB; Norris CM; Mahadevan A; Busse P; Wirth L; Goguen LA; Sullivan CA; Costello R; Case MA; Posner MR
    Oncologist; 2003; 8(1):35-44. PubMed ID: 12604730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.